Scalper1 News
Shares of specialty-drug giant Allergan (AGN) were seesawing Tuesday after the company issued guidance late Monday for the rest of the year following the sale of its generics business. Allergan said it expects second-half revenue of around $8 billion, with EPS of $6.25 to $6.65, including $750 million in interest expenses. The company said that longer term, it expects 10% growth in its branded product sales and gross profit margins of 77% to 79%. Scalper1 News
Scalper1 News